BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 10759405)

  • 1. Matrix metalloproteinase inhibitors: applications in oncology.
    Yip D; Ahmad A; Karapetis CS; Hawkins CA; Harper PG
    Invest New Drugs; 1999; 17(4):387-99. PubMed ID: 10759405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matrix metalloproteinase inhibitors.
    Wojtowicz-Praga SM; Dickson RB; Hawkins MJ
    Invest New Drugs; 1997; 15(1):61-75. PubMed ID: 9195290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix metalloproteinase inhibitors as anticancer agents.
    Konstantinopoulos PA; Karamouzis MV; Papatsoris AG; Papavassiliou AG
    Int J Biochem Cell Biol; 2008; 40(6-7):1156-68. PubMed ID: 18164645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matrix metalloproteinase inhibitors: present achievements and future prospects.
    Denis LJ; Verweij J
    Invest New Drugs; 1997; 15(3):175-85. PubMed ID: 9387040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix metalloproteinases. Novel targets for directed cancer therapy.
    Yu AE; Hewitt RE; Connor EW; Stetler-Stevenson WG
    Drugs Aging; 1997 Sep; 11(3):229-44. PubMed ID: 9303281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.
    Zucker S; Cao J; Chen WT
    Oncogene; 2000 Dec; 19(56):6642-50. PubMed ID: 11426650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress in the development of matrix metalloproteinase inhibitors.
    Tu G; Xu W; Huang H; Li S
    Curr Med Chem; 2008; 15(14):1388-95. PubMed ID: 18537616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matrix metalloproteinase inhibitors.
    Ramnath N; Creaven PJ
    Curr Oncol Rep; 2004 Mar; 6(2):96-102. PubMed ID: 14751086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix metalloproteinase inhibition: a review of anti-tumour activity.
    Brown PD; Giavazzi R
    Ann Oncol; 1995 Dec; 6(10):967-74. PubMed ID: 8750146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The matrix metalloproteinases and their inhibitors in the treatment of pancreatic cancer.
    Jones L; Ghaneh P; Humphreys M; Neoptolemos JP
    Ann N Y Acad Sci; 1999 Jun; 880():288-307. PubMed ID: 10415874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat.
    Rasmussen HS; McCann PP
    Pharmacol Ther; 1997; 75(1):69-75. PubMed ID: 9364582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of tumour cell apoptosis by matrix metalloproteinase inhibitors: new tricks from a (not so) old drug.
    Mitsiades N; Poulaki V; Mitsiades CS; Anderson KC
    Expert Opin Investig Drugs; 2001 Jun; 10(6):1075-84. PubMed ID: 11772236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors of gelatinases (MMP-2 and MMP-9) for the management of hematological malignancies.
    Das S; Amin SA; Jha T
    Eur J Med Chem; 2021 Nov; 223():113623. PubMed ID: 34157437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical studies with matrix metalloproteinase inhibitors.
    Brown PD
    APMIS; 1999 Jan; 107(1):174-80. PubMed ID: 10190295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matrix metalloproteinase inhibitors: do they have a place in anticancer therapy?
    Rudek MA; Venitz J; Figg WD
    Pharmacotherapy; 2002 Jun; 22(6):705-20. PubMed ID: 12066962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of matrix metalloproteinases and their inhibitors in pancreatic cancer.
    Evans JD; Ghaneh P; Kawesha A; Neoptolemos JP
    Digestion; 1997; 58(6):520-8. PubMed ID: 9438596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matrix metalloproteinase inhibitors for cancer therapy:the current situation and future prospects.
    Fingleton B
    Expert Opin Ther Targets; 2003 Jun; 7(3):385-97. PubMed ID: 12783574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials.
    Pavlaki M; Zucker S
    Cancer Metastasis Rev; 2003; 22(2-3):177-203. PubMed ID: 12784996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matrix metalloproteinases in cancer: prognostic markers and targets for therapy (review).
    Duffy MJ; McCarthy K
    Int J Oncol; 1998 Jun; 12(6):1343-8. PubMed ID: 9592197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matrix metalloproteinase inhibitors.
    Brown PD
    Breast Cancer Res Treat; 1998; 52(1-3):125-36. PubMed ID: 10066077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.